Brief: Nabriva Therapeutics Reports Positive Topline Results From Phase 1 Trial Of Cystic Fibrosis Drug
28/11/2022 12:07
Nov 28 (Reuters) - Nabriva Therapeutics PLC NBRV.O :
* NABRIVA THERAPEUTICS ANNOUNCES POSITIVE TOPLINE RESULTS
FROM
PHASE 1 TRIAL OF XENLETA® (LEFAMULIN) IN ADULT PATIENTS WITH
CYSTIC FIBROSIS
* NABRIVA THERAPEUTICS PLC - PK DATA AND SAFETY PROFILE
CONSISTENT
WITH PREVIOUS STUDIES IN HEALTHY SUBJECTS
* NABRIVA THERAPEUTICS PLC - RESULTS SUPPORT POTENTIAL
UTILITY OF
LEFAMULIN IN PATIENTS WITH CYSTIC FIBROSIS
* NABRIVA THERAPEUTICS PLC - LOOK FORWARD TO SHARING
COMPLETE
RESULTS WITH MEDICAL COMMUNITY IN FIRST HALF OF 2023
Source text for Eikon: ID:nGNX4YhSPz
Further company coverage: NBRV.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Nabriva Therapeutics
See all newsBrief: Nabriva Therapeutics And Units Enter Asset Purchase Agreement With Sumitomo Pharma
Brief: Nabriva Therapeutics Says Received Delisting Determination Letter From Nasdaq
Brief: Nabriva Therapeutics Receives Notice Of Delisting Or Failure To Satisfy Continued Listing Rule From Nasdaq
Brief: Nabriva Therapeutics - On Jan 31, Co's Unit Entered Into Letter Agreement With 2 Units Of Merck & Co, About Distribution Agreement, Dated July 15, 2020
Brief: Nabriva Therapeutics Provides Corporate Update